Home › Kanser sa Bato (Renal Cell Carcinoma)
Pag-aaral pangklinika para sa Kanser sa Bato (Renal Cell Carcinoma) na nagre-recruit sa U.S.
134 pag-aaral para sa Kanser sa Bato (Renal Cell Carcinoma) ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Houston, TX35 pag-aaral
- New York City, NY27 pag-aaral
- Nashville, TN23 pag-aaral
- Dallas, TX23 pag-aaral
- St. Louis, MO23 pag-aaral
- Los Angeles, CA20 pag-aaral
- Boston, MA16 pag-aaral
- Baldwin Park, CA16 pag-aaral
- Philadelphia, PA15 pag-aaral
- Pittsburgh, PA15 pag-aaral
- Queens, NY15 pag-aaral
- Cleveland, OH14 pag-aaral
- Jacksonville, FL14 pag-aaral
- Rochester, MN14 pag-aaral
- San Diego, CA14 pag-aaral
- Washington, DC13 pag-aaral
- New Haven, CT13 pag-aaral
- Columbus, OH13 pag-aaral
- Omaha, NE12 pag-aaral
- Edison, NJ12 pag-aaral
- Durham, NC12 pag-aaral
- San Antonio, TX12 pag-aaral
- Ann Arbor, MI12 pag-aaral
- Phoenix, AZ11 pag-aaral
- Portland, OR11 pag-aaral
- San Francisco, CA11 pag-aaral
- Detroit, MI10 pag-aaral
- Baltimore, MD10 pag-aaral
- Grand Rapids, MI10 pag-aaral
- Atlanta, GA10 pag-aaral
- Arlington, VA9 pag-aaral
- Seattle, WA9 pag-aaral
- Aurora, CO9 pag-aaral
- Santa Monica, CA8 pag-aaral
- Charlotte, NC8 pag-aaral
- Milwaukee, WI8 pag-aaral
- Miami, FL8 pag-aaral
- Chicago, IL8 pag-aaral
- Denver, CO8 pag-aaral
- Oklahoma City, OK8 pag-aaral
Ayos sa estado
- Alabama7 pag-aaral
- Arizona22 pag-aaral
- Arkansas6 pag-aaral
- California51 pag-aaral
- Colorado15 pag-aaral
- Connecticut13 pag-aaral
- District of Columbia7 pag-aaral
- Florida31 pag-aaral
- Georgia12 pag-aaral
- Idaho4 pag-aaral
- Illinois14 pag-aaral
- Indiana8 pag-aaral
- Iowa9 pag-aaral
- Kansas5 pag-aaral
- Kentucky9 pag-aaral
- Louisiana7 pag-aaral
- Maine3 pag-aaral
- Maryland17 pag-aaral
- Massachusetts18 pag-aaral
- Michigan29 pag-aaral
- Minnesota20 pag-aaral
- Mississippi4 pag-aaral
- Missouri23 pag-aaral
- Montana3 pag-aaral
- Nebraska12 pag-aaral
- Nevada4 pag-aaral
- New Hampshire4 pag-aaral
- New Jersey16 pag-aaral
- New Mexico5 pag-aaral
- New York36 pag-aaral
- North Carolina19 pag-aaral
- North Dakota3 pag-aaral
- Ohio26 pag-aaral
- Oklahoma8 pag-aaral
- Oregon11 pag-aaral
- Pennsylvania26 pag-aaral
- Rhode Island6 pag-aaral
- South Carolina12 pag-aaral
- South Dakota4 pag-aaral
- Tennessee27 pag-aaral
- Texas56 pag-aaral
- Utah7 pag-aaral
- Vermont3 pag-aaral
- Virginia13 pag-aaral
- Washington12 pag-aaral
- West Virginia4 pag-aaral
- Wisconsin12 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05536141Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT07300241Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06265285A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06270706Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Nagre-recruitPhase 2
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05155033A Phase 1 Study of the Safety and Tolerability of CTX-10726
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT07419841Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Nagre-recruitPhase 1/2
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT07049926A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06234605Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT05176483Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT05287945The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07285044Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT03866382Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Nagre-recruitPhase 2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT04981509REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07594106DESTINY-PANTUMOUR04
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 130 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07124000Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT04981119A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07489495Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma
Nagre-recruitPhase 1
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07748988Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06047379A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07293351Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06863311A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT07688187Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT05267626Photodynamic Diagnosis of Kidney Cancer Using Fluorescence Endoscopy and Oral 5-ALA
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 18, 2026 · NCT07828704Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.